Dr Zhang on the Rationale for Investigating Sintilimab/Axitinib in FH-Deficient RCC
May 23rd 2023Xingming Zhang, MD, discusses the rationale for investigating the combination of sintilimab and axitinib in patients with advanced fumarate hydratase-deficient renal cell carcinoma in a phase 2 trial.
Read More